Cyclerion Therapeutics, Inc.
CYCN
$3.13
-$0.05-1.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -43.24% | 351.03% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.24% | 351.03% | -- | -- | -- |
| Cost of Revenue | 826.79% | 329.63% | -46.67% | -18.18% | 131.82% |
| Gross Profit | -71.09% | 366.37% | 135.24% | 202.27% | 894.32% |
| SG&A Expenses | 7.69% | 23.53% | 33.62% | -4.57% | -36.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.87% | 42.28% | 27.53% | -4.94% | -27.35% |
| Operating Income | -266.93% | 10.82% | -20.81% | 9.95% | 127.97% |
| Income Before Tax | -250.75% | -34.99% | 75.49% | 7.33% | 131.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -250.75% | -34.99% | 75.49% | 7.33% | 131.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -250.75% | -34.99% | 75.49% | 7.33% | 131.29% |
| EBIT | -266.93% | 10.82% | -20.81% | 9.95% | 127.97% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -200.58% | -5.73% | 79.97% | 9.57% | 130.22% |
| Normalized Basic EPS | -200.54% | -5.70% | -1.46% | 9.58% | 130.21% |
| EPS Diluted | -200.58% | -5.73% | 79.97% | 9.57% | 130.19% |
| Normalized Diluted EPS | -200.54% | -5.70% | -1.46% | 9.58% | 130.21% |
| Average Basic Shares Outstanding | 49.92% | 27.67% | 22.35% | 2.49% | 3.54% |
| Average Diluted Shares Outstanding | 49.92% | 27.67% | 22.35% | 2.49% | 3.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |